NovaBridge Biosciences - Asset Resilience Ratio
NovaBridge Biosciences (NBP) has an Asset Resilience Ratio of 0.08% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check NBP strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how NovaBridge Biosciences's Asset Resilience Ratio has changed over time. See NovaBridge Biosciences net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down NovaBridge Biosciences's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of NovaBridge Biosciences.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.50 Million | 0.08% |
| Total Liquid Assets | $1.50 Million | 0.08% |
Asset Resilience Insights
- Limited Liquidity: NovaBridge Biosciences maintains only 0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
NovaBridge Biosciences Industry Peers by Asset Resilience Ratio
Compare NovaBridge Biosciences's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for NovaBridge Biosciences (2017–2024)
The table below shows the annual Asset Resilience Ratio data for NovaBridge Biosciences.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.43% | $105.14 Million | $212.68 Million | +48.66pp |
| 2023-12-31 | 0.77% | $20.22 Million | $2.61 Billion | -5.01pp |
| 2022-12-31 | 5.78% | $235.43 Million | $4.07 Billion | -7.60pp |
| 2021-12-31 | 13.38% | $753.16 Million | $5.63 Billion | +12.88pp |
| 2020-12-31 | 0.50% | $31.53 Million | $6.33 Billion | -1.34pp |
| 2019-12-31 | 1.84% | $32.00 Million | $1.74 Billion | -8.93pp |
| 2018-12-31 | 10.77% | $255.96 Million | $2.38 Billion | -15.19pp |
| 2017-12-31 | 25.97% | $266.25 Million | $1.03 Billion | -- |
About NovaBridge Biosciences
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial fo… Read more